These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 18678674)
1. The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells. Kwok WW; Yang J; James E; Bui J; Huston L; Wiesen AR; Roti M Infect Immun; 2008 Oct; 76(10):4538-45. PubMed ID: 18678674 [TBL] [Abstract][Full Text] [Related]
2. Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine. Laughlin EM; Miller JD; James E; Fillos D; Ibegbu CC; Mittler RS; Akondy R; Kwok W; Ahmed R; Nepom G Infect Immun; 2007 Apr; 75(4):1852-60. PubMed ID: 17283103 [TBL] [Abstract][Full Text] [Related]
3. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N; Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399 [TBL] [Abstract][Full Text] [Related]
4. Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. Kwok WW; Tan V; Gillette L; Littell CT; Soltis MA; LaFond RB; Yang J; James EA; DeLong JH J Immunol; 2012 Mar; 188(6):2537-44. PubMed ID: 22327072 [TBL] [Abstract][Full Text] [Related]
5. A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against Majumder S; Das S; Somani VK; Makam SS; Kingston JJ; Bhatnagar R Front Immunol; 2019; 10():498. PubMed ID: 30941133 [TBL] [Abstract][Full Text] [Related]
6. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444 [TBL] [Abstract][Full Text] [Related]
8. Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins. Martin TL; Jee J; Kim E; Steiner HE; Cormet-Boyaka E; Boyaka PN Vaccine; 2017 Apr; 35(18):2511-2519. PubMed ID: 28343781 [TBL] [Abstract][Full Text] [Related]
9. Development of a novel multiepitope chimeric vaccine against anthrax. Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633 [TBL] [Abstract][Full Text] [Related]
10. Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design. Altmann DM Expert Rev Vaccines; 2015 Mar; 14(3):429-34. PubMed ID: 25400140 [TBL] [Abstract][Full Text] [Related]
11. Anthrax lethal toxin and the induction of CD4 T cell immunity. Ascough S; Ingram RJ; Altmann DM Toxins (Basel); 2012 Oct; 4(10):878-99. PubMed ID: 23162703 [TBL] [Abstract][Full Text] [Related]
12. Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen. Oscherwitz J; Quinn CP; Cease KB Vaccine; 2015 May; 33(20):2342-6. PubMed ID: 25820066 [TBL] [Abstract][Full Text] [Related]
13. Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine. Chi X; Li J; Liu W; Wang X; Yin K; Liu J; Zai X; Li L; Song X; Zhang J; Zhang X; Yin Y; Fu L; Xu J; Yu C; Chen W Clin Vaccine Immunol; 2015 May; 22(5):553-60. PubMed ID: 25787135 [TBL] [Abstract][Full Text] [Related]
14. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses. Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249 [TBL] [Abstract][Full Text] [Related]
15. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Park YS; Lee JH; Hung CF; Wu TC; Kim TW Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494 [TBL] [Abstract][Full Text] [Related]
16. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Welkos S; Little S; Friedlander A; Fritz D; Fellows P Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699 [TBL] [Abstract][Full Text] [Related]